Belinda Gray1, Jodie Ingles2, Caroline Medi3, Christopher Semsarian4. 1. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia. 2. Sydney Medical School, University of Sydney, Sydney, Australia; Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Camperdown, Australia. 3. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Camperdown, Australia. 4. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia; Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Camperdown, Australia. Electronic address: c.semsarian@centenary.org.au.
Abstract
OBJECTIVES: This study sought to determine factors predicting appropriate implantable cardioverter defibrillator (ICD) therapy in a large cohort of patients with hypertrophic cardiomyopathy (HCM). BACKGROUND: HCM is the leading cause of sudden cardiac death in those age ≤35 years. ICD therapy is offered to select patients at increased risk for sudden cardiac death. Currently, there are no clinical predictors of appropriate ICD therapy in HCM. METHODS: Patients attending the HCM clinic in Sydney, Australia, and who had undergone ICD insertion were included. Baseline data on clinical and ICD characteristics were collected. The primary endpoint was the proportion of patients who experienced at least 1 appropriate therapy from the ICD. RESULTS: Of 164 HCM patients included (62% male; mean follow-up, 6 ± 4 years [range, 0 to 19 years]), 21 patients (13%) had at least 1 appropriate therapy. Corrected QT (QTc) interval was the strongest clinical predictor of appropriate ICD therapy (458 ± 30 ms vs. 430 ± 35 ms; p = 0.001). Multivariate logistic regression analysis demonstrated a 1.2-fold increased likelihood of appropriate therapy per 10-ms increase in QTc, independent of left ventricular wall thickness (LVWT) (odds ratio: 1.2; 95% confidence interval [CI]: 1.03 to 1.39; p = 0.02) and sex (odds ratio: 1.2; 95% CI: 1.07 to 1.42; p = 0.003). On analysis of cumulative event-free survival from appropriate ICD therapy, the risk for an appropriate ICD therapy in the subgroup with prolonged QT was >3-fold that in the subgroup without prolonged QT, after adjustment for LVWT (hazard ratio: 3.2; 95% CI: 1.02 to 9.88; p = 0.047) and sex (hazard ratio, 3.7; 95% CI, 1.22 to 11.41; p = 0.02). CONCLUSIONS: The findings from this study suggest that QTc interval prolongation is a novel clinical predictor of appropriate ICD therapy in HCM.
OBJECTIVES: This study sought to determine factors predicting appropriate implantable cardioverter defibrillator (ICD) therapy in a large cohort of patients with hypertrophic cardiomyopathy (HCM). BACKGROUND: HCM is the leading cause of sudden cardiac death in those age ≤35 years. ICD therapy is offered to select patients at increased risk for sudden cardiac death. Currently, there are no clinical predictors of appropriate ICD therapy in HCM. METHODS:Patients attending the HCM clinic in Sydney, Australia, and who had undergone ICD insertion were included. Baseline data on clinical and ICD characteristics were collected. The primary endpoint was the proportion of patients who experienced at least 1 appropriate therapy from the ICD. RESULTS: Of 164 HCM patients included (62% male; mean follow-up, 6 ± 4 years [range, 0 to 19 years]), 21 patients (13%) had at least 1 appropriate therapy. Corrected QT (QTc) interval was the strongest clinical predictor of appropriate ICD therapy (458 ± 30 ms vs. 430 ± 35 ms; p = 0.001). Multivariate logistic regression analysis demonstrated a 1.2-fold increased likelihood of appropriate therapy per 10-ms increase in QTc, independent of left ventricular wall thickness (LVWT) (odds ratio: 1.2; 95% confidence interval [CI]: 1.03 to 1.39; p = 0.02) and sex (odds ratio: 1.2; 95% CI: 1.07 to 1.42; p = 0.003). On analysis of cumulative event-free survival from appropriate ICD therapy, the risk for an appropriate ICD therapy in the subgroup with prolonged QT was >3-fold that in the subgroup without prolonged QT, after adjustment for LVWT (hazard ratio: 3.2; 95% CI: 1.02 to 9.88; p = 0.047) and sex (hazard ratio, 3.7; 95% CI, 1.22 to 11.41; p = 0.02). CONCLUSIONS: The findings from this study suggest that QTc interval prolongation is a novel clinical predictor of appropriate ICD therapy in HCM.
Authors: Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan Journal: Ann Cardiothorac Surg Date: 2017-07
Authors: Mikko Jalanko; Heikki Väänänen; Mika Tarkiainen; Petri Sipola; Pertti Jääskeläinen; Kirsi Lauerma; Tiina Laitinen; Tomi Laitinen; Mika Laine; Tiina Heliö; Johanna Kuusisto; Matti Viitasalo Journal: Ann Noninvasive Electrocardiol Date: 2018-07-04 Impact factor: 1.468
Authors: Amir Toib; Chen Zhang; Giulia Borghetti; Xiaoxiao Zhang; Markus Wallner; Yijun Yang; Constantine D Troupes; Hajime Kubo; Thomas E Sharp; Eric Feldsott; Remus M Berretta; Neil Zalavadia; Danielle M Trappanese; Shavonn Harper; Polina Gross; Xiongwen Chen; Sadia Mohsin; Steven R Houser Journal: Am J Physiol Heart Circ Physiol Date: 2017-06-23 Impact factor: 4.733
Authors: Julia Münch; Ali Aydin; Anna Suling; Christian Voigt; Stefan Blankenberg; Monica Patten Journal: PLoS One Date: 2015-06-24 Impact factor: 3.240